Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.56 |
| ▸ | BRD7 | Q9NPI1 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | METAP2 | P50579 | 1/20 | 0.48 |
| ▸ | ERN1 | O75460 | 2/20 | 0.47 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.46 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.46 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.46 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | POLQ | O75417 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | NNMT | P40261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31438401 | 1.00 | BRD9 (0.56) | BRD9BRD7POLBTDP1CYP1A2 | |
| SCHEMBL10094647 | 0.84 | BRD9 (0.52) | BRD9BRD7POLBTDP1CYP1A2 | |
| SCHEMBL13500512 | 0.82 | BRD9 (0.47) | BRD9BRD7POLBTDP1ERN1 | |
| SCHEMBL14536130 | 0.80 | BRD9 (0.52) | BRD9BRD7POLBTDP1CYP1A2 | |
| SCHEMBL10094340 | 0.80 | BRD9 (0.49) | BRD9BRD7POLBTDP1CYP1A2 | |
| SCHEMBL2037315 | 0.80 | ERN1 (0.49) | BRD9BRD7POLBTDP1CYP1A2 | |
| SCHEMBL10094683 | 0.79 | PDE2A (0.44) | BRD9BRD7POLBTDP1CYP1A2 | |
| SCHEMBL28789059 | 0.79 | ERN1 (0.42) | BRD9BRD7POLBTDP1CYP1A2 | |
| SCHEMBL7708425 | 0.79 | ERN1 (0.51) | BRD9BRD7POLBTDP1CYP1A2 | |
| SCHEMBL22621616 | 0.78 | POLB (0.52) | BRD9BRD7POLBTDP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3710422-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY AND DIASTEREOMERICALLY ENRICHED CYCLOBUTANE AMINES AND AMIDES | Syngenta Participations AG (CH) | 2020-09-23 | — | — | EP | claimed |
| WO-2015178846-A1 | PROCESS FOR THE PREPARATION OF CHIRAL AMINES FROM PROCHIRAL KETONES | SP PROCESS DEVELOPMENT AB (SE) | 2015-11-26 | — | — | WO | claimed |
| WO-2015178847-A1 | PROCESS FOR THE PREPARATION OF CHIRAL AMINES BY ASYMMETRIC HYDROGENATION OF PROCHIRAL OXIMES | SP PROCESS DEVELOPMENT AB (SE) | 2015-11-26 | — | — | WO | claimed |
| US-11053188-B2 | Process for the preparation of enantiomerically and diastereomerically enriched cyclobutane amines and amides | SYNGENTA PARTICIPATIONS AG (CH) | 2021-07-06 | — | — | US | disclosed |
| US-20200407311-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY AND DIASTEREOMERICALLY ENRICHED CYCLOBUTANE AMINES AND AMIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2020-12-31 | — | — | US | disclosed |
| EP-3710422-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY AND DIASTEREOMERICALLY ENRICHED CYCLOBUTANE AMINES AND AMIDES | Syngenta Participations AG (CH) | 2020-09-23 | — | — | EP | disclosed |
| WO-2015178846-A1 | PROCESS FOR THE PREPARATION OF CHIRAL AMINES FROM PROCHIRAL KETONES | SP PROCESS DEVELOPMENT AB (SE) | 2015-11-26 | — | — | WO | disclosed |
| WO-2015178847-A1 | PROCESS FOR THE PREPARATION OF CHIRAL AMINES BY ASYMMETRIC HYDROGENATION OF PROCHIRAL OXIMES | SP PROCESS DEVELOPMENT AB (SE) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407311-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY AND DIASTEREOMERICALLY ENRICHED CYCLOBUTANE AMINES AND AMIDES | TBCB, ADORA2B, ADRA2B | BRD9 2552/4885BRD7 1094/4885POLB 243/4885 |
| US-11053188-B2 | Process for the preparation of enantiomerically and diastereomerically enriched cyclobutane amines and amides | TBCB, ADORA2B, CCNB3 | BRD9 2484/4885BRD7 1050/4885POLB 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.